Literature DB >> 16610061

Cryptogenic cirrhosis in the region where obesity is not prevalent.

Hideyuki Kojima1, Shinya Sakurai, Masahiko Matsumura, Norie Umemoto, Masahito Uemura, Hiroyo Morimoto, Yasuhiro Tamagawa, Hiroshi Fukui.   

Abstract

AIM: Recent studies have demonstrated that obesity is the common feature of cryptogenic cirrhosis (CC) and non-alcoholic steatohepatitis. However, there is little information on CC in the region where obesity is not prevalent.
METHODS: The clinical features, and the liver-related morbidity and mortality of CC were analyzed in Japan where the prevalence of obesity is low. Among 652 cirrhotic patients, we identified 29 patients (4.4%) with CC. Of these, 24 CC patients who were followed up for more than 6 months were compared in a case-control study with age-, sex-, and Child-Pugh score-matched controls having cirrhosis of viral etiology.
RESULTS: Obesity (BMI>or=25 kg/m(2)), diabetes mellitus, and hypertriglyceridemia were more frequent, and the visceral fat area was larger in the CC patients than in the controls. The indices of insulin resistance were higher and the serum aminotransferase levels were lower in the CC patients than in the controls. Logistic regression analysis identified the elevated hemoglobin A1c, BMI>or=25 kg/m(2), and normal aminotransferase levels as independent predictors of CC. Kaplan-Meier analysis demonstrated lower occurrence of hepatocellular carcinoma and higher survival rate in the CC than in the controls in contrast to the similar cumulative probability of liver-related morbidity between those groups.
CONCLUSION: CC more frequently presents with the clinical features suggestive of non-alcoholic steatohepatitis compared with controls even in the region where obesity is not prevalent. The lower occurrence of hepatocellular carcinoma and higher survival rate may indicate an indolent clinical course in CC as compared with viral cirrhosis.

Entities:  

Mesh:

Year:  2006        PMID: 16610061      PMCID: PMC4087689          DOI: 10.3748/wjg.v12.i13.2080

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  Tamoxifen-induced fatty liver in patients with breast cancer.

Authors:  Y Ogawa; Y Murata; A Nishioka; T Inomata; S Yoshida
Journal:  Lancet       Date:  1998-03-07       Impact factor: 79.321

2.  Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation.

Authors:  Gamze Ayata; Fredric D Gordon; W David Lewis; Elizabeth Pomfret; James J Pomposelli; Roger L Jenkins; Urmila Khettry
Journal:  Hum Pathol       Date:  2002-11       Impact factor: 3.466

3.  Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study.

Authors:  A Poonawala; S P Nair; P J Thuluvath
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

4.  Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis.

Authors:  Vlad Ratziu; Luminita Bonyhay; Vincent Di Martino; Frederic Charlotte; Lucas Cavallaro; Marie-Hélène Sayegh-Tainturier; Philippe Giral; André Grimaldi; Pierre Opolon; Thierry Poynard
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

5.  Association of plasminogen activator inhibitor-1 with insulin resistance in Japan where obesity is rare.

Authors:  Takeyuki Nakamura; Hisashi Adachi; Yuji Hirai; Akira Satoh; Masanao Ohuchida; Tsutomu Imaizumi
Journal:  Metabolism       Date:  2003-02       Impact factor: 8.694

6.  Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies.

Authors:  Eduardo Fassio; Estela Alvarez; Nora Domínguez; Graciela Landeira; Cristina Longo
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

7.  A novel technique for the determination of body fat by computed tomography.

Authors:  K Tokunaga; Y Matsuzawa; K Ishikawa; S Tarui
Journal:  Int J Obes       Date:  1983

8.  Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1995

9.  Prevalence and trends in obesity among US adults, 1999-2000.

Authors:  Katherine M Flegal; Margaret D Carroll; Cynthia L Ogden; Clifford L Johnson
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

10.  Liver damage in obese patients.

Authors:  Antonio Del Gaudio; Luca Boschi; Giovanni-Alberto Del Gaudio; Laura Mastrangelo; Daniela Munari
Journal:  Obes Surg       Date:  2002-12       Impact factor: 4.129

View more
  14 in total

Review 1.  Cryptogenic cirrhosis: what are we missing?

Authors:  Stephen Caldwell
Journal:  Curr Gastroenterol Rep       Date:  2010-02

Review 2.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

3.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

4.  Increased age, male gender, and cirrhosis, but not steatosis or a positive viral serology, negatively impact the life expectancy of patients who undergo liver biopsy.

Authors:  Mitchell S Wachtel; Yan Zhang; Kim E Kaye; Maurizio Chiriva-Internati; Eldo E Frezza
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

5.  Non-alcoholic fatty liver disease-related hepatocellular carcinoma: a sleeping tiger in the Asia Pacific.

Authors:  Roslyn Vongsuvanh; David van der Poorten; Jacob George
Journal:  Hepatol Int       Date:  2013-07-31       Impact factor: 6.047

Review 6.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

Review 7.  Epidemiology of hepatocellular carcinoma: consider the population.

Authors:  Sahil Mittal; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2013-07       Impact factor: 3.062

8.  Liver biopsy for histological assessment: The case in favor.

Authors:  Khalid A Alswat; Khalid Mumtaz; Wasim Jafri
Journal:  Saudi J Gastroenterol       Date:  2010 Apr-Jun       Impact factor: 2.485

9.  Risk factors of cryptogenic hepatocellular carcinoma in patients with low body mass index or without metabolic syndrome.

Authors:  Hwa Young Song; Hyo Keun Lee; June Sung Lee; Jong Yeon Kim; Yun Hyuk Yim; Tae Jun Song; Won Ki Bae; Nam-Hoon Kim; Kyung-Ah Kim
Journal:  Korean J Intern Med       Date:  2012-02-28       Impact factor: 2.884

10.  Survival of patients with alcoholic and cryptogenic cirrhosis without liver transplantation: a single center retrospective study.

Authors:  Sudul Mananjala Senanayake; Madunil Anuk Niriella; Sanjaya Kumara Weerasinghe; Anuradhani Kasturiratne; Jerome Praneeth de Alwis; Arjuna Priyadarsin de Silva; Anuradha Supun Dassanayake; Hithanadura Janaka de Silva
Journal:  BMC Res Notes       Date:  2012-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.